GlassScriptPhysician profile
Brad L Lewis
NPI 1730315748
$5,627.01
in general payments reported to CMS, 2019-2025
30 companies · $1,080 in 2025
The $1,080 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $888 · 2022: $1,333 · 2023: $1,168 · 2024: $1,158 · 2025: $1,080.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,406.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $926.68 | 2021-2024 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $895.24 | 2023-2025 | Orgovyx, Gemtesa |
| Pfizer INC. | $563.94 | 2021-2025 | |
| Janssen Biotech, INC. | $503.08 | 2021-2025 | Erleada |
| Abbvie INC. | $356.92 | 2021-2025 | |
| Tolmar, INC. | $356.24 | 2023-2025 | Jatenzo, Eligard |
| Merck Sharp & Dohme LLC | $293.55 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Hollister Incorporated | $262.51 | 2022-2023 | Onli, Infyna Chic, Vapro |
| Myovant Sciences INC. | $254.90 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $155.61 | 2021-2022 | |
| Progenics Pharmaceuticals, INC. | $119.27 | 2022-2024 | |
| C. R. Bard, INC. & Subsidiaries | $119.27 | 2022-2025 | Bard Urinary Drainage Bag, Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Boston Scientific Corporation | $117.00 | 2022-2025 | Ams 700, Axonics |
| Urovant Sciences INC | $104.06 | 2022 | |
| Alexion Pharmaceuticals, INC. | $91.07 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $86.04 | 2022-2023 | Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $64.94 | 2023-2025 | |
| Verity Pharmaceuticals INC. | $60.17 | 2025 | Trelstar, Tlando |
| Blue Earth Diagnostics | $50.81 | 2021 | |
| Palette Life Sciences, INC. | $39.98 | 2023 | |
| Ferring Pharmaceuticals INC. | $38.44 | 2025 | Adstiladrin |
| Endo Pharmaceuticals INC. | $21.04 | 2023 | Xiaflex |
| Dendreon Pharmaceuticals LLC | $20.86 | 2023 | Provenge |
| Teleflex LLC | $20.54 | 2023 | Urolift |
| Urogen Pharma, INC. | $20.40 | 2022 | |
| Halozyme INC | $18.59 | 2023 | |
| Olympus America INC. | $18.18 | 2025 | Itind System |
| Phathom Pharmaceuticals, INC. | $17.73 | 2024 | Voquezna |
| Dentsply Ih Ab | $16.53 | 2021 | |
| Amgen INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.